Maria Luisa Guerrera

8PUBLICATIONS
24CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 08, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

|Apr 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

|Mar 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

Jorge J Castillo, Andrew R Branagan, Alberto Guijosa

|Feb 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Hao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu

|Feb 03, 2026
Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterations.

Alberto Guijosa, Nicholas Tsakmaklis, Margaret Kobs

|Jan 16, 2026
Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia.

Nickolas Tsakmaklis, Zachary R Hunter, Xia Liu

Pageof 2

Frequent Collaborators

8 joint publications

Jorge J Castillo

8 joint publications

Zachary R Hunter

8 joint publications

Steven P Treon

7 joint publications

Andrew R Branagan